167 related articles for article (PubMed ID: 24428704)
1. Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
Patrick K; Wade R; Goulden N; Rowntree C; Hough R; Moorman AV; Mitchell CD; Vora A
Br J Haematol; 2014 May; 165(4):552-5. PubMed ID: 24428704
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
Hough R; Rowntree C; Goulden N; Mitchell C; Moorman A; Wade R; Vora A
Br J Haematol; 2016 Feb; 172(3):439-51. PubMed ID: 26683485
[TBL] [Abstract][Full Text] [Related]
4. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
5. Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report.
Zawitkowska J; Odój T; Drabko K; Zaucha-Prażmo A; Rudnicka J; Romiszewski M; Matysiak M; Kwiecińska K; Ćwiklińska M; Balwierz W; Owoc-Lempach J; Derwich K; Wachowiak J; Niedźwiecki M; Adamkiewicz-Drożyńska E; Trelińska J; Młynarski W; Kołtan A; Wysocki M; Tomaszewska R; Szczepański T; Płonowski M; Krawczuk-Rybak M; Ociepa T; Urasiński T; Mizia-Malarz A; Sobol-Milejska G; Karolczyk G; Kowalczyk J
Pediatr Hematol Oncol; 2017 May; 34(4):199-205. PubMed ID: 29040012
[TBL] [Abstract][Full Text] [Related]
6. Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.
Hitzler JK; He W; Doyle J; Cairo M; Camitta BM; Chan KW; Diaz Perez MA; Fraser C; Gross TG; Horan JT; Kennedy-Nasser AA; Kitko C; Kurtzberg J; Lehmann L; O'Brien T; Pulsipher MA; Smith FO; Zhang MJ; Eapen M; Carpenter PA;
Pediatr Blood Cancer; 2014 Jun; 61(6):1126-8. PubMed ID: 24391118
[TBL] [Abstract][Full Text] [Related]
7. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
8. Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003.
Bartram J; Wade R; Vora A; Hancock J; Mitchell C; Kinsey S; Steward C; Moppett J; Goulden N
Arch Dis Child; 2016 May; 101(5):449-54. PubMed ID: 26865705
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
10. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.
Buitenkamp TD; Izraeli S; Zimmermann M; Forestier E; Heerema NA; van den Heuvel-Eibrink MM; Pieters R; Korbijn CM; Silverman LB; Schmiegelow K; Liang DC; Horibe K; Arico M; Biondi A; Basso G; Rabin KR; Schrappe M; Cario G; Mann G; Morak M; Panzer-Grümayer R; Mondelaers V; Lammens T; Cavé H; Stark B; Ganmore I; Moorman AV; Vora A; Hunger SP; Pui CH; Mullighan CG; Manabe A; Escherich G; Kowalczyk JR; Whitlock JA; Zwaan CM
Blood; 2014 Jan; 123(1):70-7. PubMed ID: 24222333
[TBL] [Abstract][Full Text] [Related]
11. Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.
Athale UH; Puligandla M; Stevenson KE; Asselin B; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Harris MH; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Oct; 65(10):e27256. PubMed ID: 29878490
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with Down syndrome and acute leukemia: A retrospective observational study.
Schmidt MP; Colita A; Ivanov AV; Coriu D; Miron IC
Medicine (Baltimore); 2021 Oct; 100(40):e27459. PubMed ID: 34622870
[TBL] [Abstract][Full Text] [Related]
13. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Biondi A; Schrappe M; De Lorenzo P; Castor A; Lucchini G; Gandemer V; Pieters R; Stary J; Escherich G; Campbell M; Li CK; Vora A; Aricò M; Röttgers S; Saha V; Valsecchi MG
Lancet Oncol; 2012 Sep; 13(9):936-45. PubMed ID: 22898679
[TBL] [Abstract][Full Text] [Related]
14. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment.
Chessells JM; Harrison G; Richards SM; Bailey CC; Hill FG; Gibson BE; Hann IM
Arch Dis Child; 2001 Oct; 85(4):321-5. PubMed ID: 11567943
[TBL] [Abstract][Full Text] [Related]
15. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort.
Essig S; Li Q; Chen Y; Hitzler J; Leisenring W; Greenberg M; Sklar C; Hudson MM; Armstrong GT; Krull KR; Neglia JP; Oeffinger KC; Robison LL; Kuehni CE; Yasui Y; Nathan PC
Lancet Oncol; 2014 Jul; 15(8):841-51. PubMed ID: 24954778
[TBL] [Abstract][Full Text] [Related]
16. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Parker C; Waters R; Leighton C; Hancock J; Sutton R; Moorman AV; Ancliff P; Morgan M; Masurekar A; Goulden N; Green N; Révész T; Darbyshire P; Love S; Saha V
Lancet; 2010 Dec; 376(9757):2009-17. PubMed ID: 21131038
[TBL] [Abstract][Full Text] [Related]
17. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group.
Dördelmann M; Schrappe M; Reiter A; Zimmermann M; Graf N; Schott G; Lampert F; Harbott J; Niemeyer C; Ritter J; Dörffel W; Nessler G; Kühl J; Riehm H
Leukemia; 1998 May; 12(5):645-51. PubMed ID: 9593260
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome.
Meyr F; Escherich G; Mann G; Klingebiel T; Kulozik A; Rossig C; Schrappe M; Henze G; von Stackelberg A; Hitzler J
Br J Haematol; 2013 Jul; 162(1):98-106. PubMed ID: 23594030
[TBL] [Abstract][Full Text] [Related]
20. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952.
Bassal M; La MK; Whitlock JA; Sather HN; Heerema NA; Gaynon PS; Stork LC
Pediatr Blood Cancer; 2005 Jan; 44(1):21-8. PubMed ID: 15368546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
